WHO WE ARE

More than 200 products
In over 90 countries
Reaching a diverse patient population

Concordia is an international specialty pharmaceutical company with a platform to supply patients around the world with quality medicines.
# SENIOR MANAGEMENT TEAM

<table>
<thead>
<tr>
<th>SENIOR MANAGEMENT</th>
<th>EXPERIENCE</th>
</tr>
</thead>
</table>
| Allan Oberman              | • Sagent Pharmaceuticals Inc: Chief Executive Officer  
                             • Teva Americas Generics: President and CEO  
                             • Teva EMIA: President                                                                 |
| Wayne Kreppner             | • Co-founder and Vice President of Product Development at Trimel Pharmaceuticals  
                             • Various senior roles in regulatory affairs and operations at Biovail Corporation     |
| Graeme Duncan              | • 20+ years healthcare and life sciences experience  
                             • Senior Commercial, Strategy and General Management roles at GlaxoSmithKline, IVAX  
                             Pharmaceuticals and Healthcare at Home                                                                 |
| Francesco Tallarico        | • Fasken Martineau DuMoulin LLP  
                             • Instrumental in the dual listing and global expansion of Concordia                  |
Global commercial footprint

Enables us to submit, gain regulatory approval, launch, in-license, supply and distribute products into more than 90 markets around the globe.

Network of development partners and contract manufacturers

Serves as our product development and manufacturing resource. Allows us to deploy capital to invest in product development, acquisitions and in-licensing arrangements.

Lean cost structure and efficient operating model

Approximately half of the Company’s employees are based in our center of excellence in Mumbai, which serves as a support hub for our global business.
International footprint with a direct or indirect presence in more than 90 countries.
## SIGNIFICANT PRODUCTS

<table>
<thead>
<tr>
<th>Branded Name</th>
<th>Molecule</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levothyroxine sodium</td>
<td>Hypothyroidism</td>
<td></td>
</tr>
<tr>
<td>Macrobid®</td>
<td>Nitrofurantoin</td>
<td>Urinary tract infections</td>
</tr>
<tr>
<td>Fusidic acid</td>
<td></td>
<td>Bacterial conjunctivitis</td>
</tr>
<tr>
<td>Liothyronine sodium</td>
<td></td>
<td>Severe hypothyroid states</td>
</tr>
</tbody>
</table>

## BRANDED AND GENERIC PRODUCTS
## SIGNIFICANT PRODUCTS

<table>
<thead>
<tr>
<th>Branded Name</th>
<th>Molecule</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Donnatal®</em></td>
<td>Phenobarbital + belladonna alkaloids</td>
<td>Irritable bowel syndrome</td>
</tr>
<tr>
<td><em>Zonegran®</em></td>
<td>Zonisamide</td>
<td>Epilepsy</td>
</tr>
<tr>
<td><em>Plaquenil®</em></td>
<td>Hydroxychloroquine sulfate</td>
<td>Inflammatory Conditions</td>
</tr>
</tbody>
</table>
Photodynamic Therapy (PDT) with Photofrin®

FDA-approved drug treatment for non-small cell lung cancer, esophageal cancer, and high-grade dysplasia in Barrett’s esophagus
CONSOLIDATED FINANCIAL OVERVIEW

2016 FINANCIALS

Revenue
US$816.1 million

Gross Profit
US$594.9 million

2016 revenue breakdown by segment (approximate)

- North America segment 30%
- International segment 68%
- More than 90 countries worldwide

2016 product mix (approximate % of total consolidated revenue)

- Donnatal®
- Plaquenil® and AG
- Tetroxin® (liothyronine sodium)
- Macrobid® (nitrofurantoin)
- Fucithalmic® (fusidic acid)
- Zonegran®
- Eltroxin® (levothyroxine sodium)
- Other

Diversified portfolio with no single product accounting for more than 10% of total 2016 revenues
LOOKING FORWARD
2017 OVERARCHING PRIORITY - STABILIZE THE BUSINESS

- Excellence in operational execution
- Strengthening financial management and financial discipline
- Expanding our portfolio
- Emphasizing stakeholder outreach
- Developing a comprehensive long-term growth strategy
<table>
<thead>
<tr>
<th><strong>PRODUCT DEVELOPMENT AND LAUNCHES</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>10</strong> Products approved or awaiting regulatory approval in various countries</td>
</tr>
<tr>
<td><strong>8</strong> Products under development, which we anticipate launching in the next three to five years</td>
</tr>
<tr>
<td><strong>Up To 14</strong> Products for potential development with our network of external partners</td>
</tr>
</tbody>
</table>
IR CONTACT DETAILS

CONCORDIA INTERNATIONAL CORP.
277 Lakeshore Road E.
Suite 302, Oakville
Ontario, Canada
L6J 1H9
(t) +1.905.842.5150 x 240
(f) +1.905.842.5154
(e) adam.peeler@concordiarx.com
www.concordiarx.com
Questions?